CompletedNot Applicable

Prophylaxis of Febrile Neutropenia With Lactoferrin in Oncohematologic Children Undergoing Induction Chemotherapy

Italy160 participantsStarted 2016-10-06

Plain-language summary

Test, in a randomized phase II trial, the safety and efficacy of lactoferrin prophylaxis in preventing the occurrence of febrile neutropenia and sepsis, with particular regard to forms due to multidrug-resistant Gram-negative bacteria.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients with severe neutropenia lasting \>7 days: * non-High Risk Acute Lymphoblastic Leukemia ( ALL) under induction treatment * Acute Myeloid Leukemia (AML) (first two cycles of treatment) * B cell - non Hodgkin Lymphoma (NHL) Ability to take oral lactoferrin therapy and perform the diagnostic tests established by the protocol Exclusion Criteria: * Previous chemotherapy treatments * Past history of colonization/infection by multidrug-resistant pathogens * Inability to take LF by mouth * Refusal to participate in the study

What they're measuring

Primary Outcome

Timeframe: From treatment up to 90 days

Trial details

NCT IDNCT07113314

SponsorFondazione IRCCS Policlinico San Matteo di Pavia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-03-03

View on ClinicalTrials.gov More Febrile Neutropenia (FN) trials